Show simple item record

dc.contributor.authorCripps, Allanen_US
dc.contributor.authorPeek, Keithen_US
dc.contributor.authorDunkley, Margareten_US
dc.contributor.authorVento, Kevinen_US
dc.contributor.authorK. Marjason, Joanneen_US
dc.contributor.authorMcIntyre, Madonnaen_US
dc.contributor.authorSizer, Philen_US
dc.contributor.authorCroft, Duncanen_US
dc.contributor.authorSedlak-Weinstein, Lisen_US
dc.date.accessioned2017-05-03T14:29:34Z
dc.date.available2017-05-03T14:29:34Z
dc.date.issued2006en_US
dc.date.modified2009-09-04T06:04:51Z
dc.identifier.issn00199567en_US
dc.identifier.doi10.1128/IAI.74.2.968-974.2006en_AU
dc.identifier.urihttp://hdl.handle.net/10072/11321
dc.description.abstractThis study examines the safety and immunogenicity of an oral, whole-cell Pseudomonas aeruginosa vaccine administered to healthy volunteers. Thirty subjects received an oral dose of Pseudostat in two timed, measured doses with serological follow-up to 56 days postvaccination. Following vaccination, several individuals were identified as antibody responders for all three immunoglobulin (Ig) isotypes tested, specifically against whole-cell P. aeruginosa extract and outer membrane proteins F and I. The mean pooled lipopolysaccharide antigen-specific IgA showed the most significant and constant increases in titer postdose, with a similar increase in titer for whole-cell P. aeruginosa extract-specific IgA. The results demonstrated an increased phagocytic ability of the selected macrophage cell line in post vaccination sera. Furthermore a significant increase in intracellular macrophage killing of opsonized P. aeruginosa was also demonstrated (82% on day 14 postdose) in the presence of the postvaccination sera. The safety component of the study did not show any vaccine-attributable adverse effects in any of the subjects, as documented by clinical evidence, hematology, and biochemistry profiles. We conclude that Pseudostat is safe and immunogenic in humans at this dose and that further studies to determine the appropriate dosage and efficacy are needed. In our study, we have shown that the most significant and sustained responses to oral vaccination in human adult volunteers were serum IgA levels and that pooled sera collected postimmunization have an increased capacity to promote opsonophagocytotic killing of P. aeruginosa.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.format.extent117304 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherAmerican Society for Microbiologyen_US
dc.publisher.placeWashington, DCen_US
dc.publisher.urihttp://iai.asm.org/en_AU
dc.relation.ispartofstudentpublicationNen_AU
dc.relation.ispartofpagefrom968en_US
dc.relation.ispartofpageto974en_US
dc.relation.ispartofissue2en_US
dc.relation.ispartofjournalInfection and Immunityen_US
dc.relation.ispartofvolume74en_US
dc.rights.retentionYen_AU
dc.subject.fieldofresearchcode329999en_US
dc.titleSafety and immunogenicity of an oral inactivated whole-cell Pseudomonas aeruginosa vaccine administered to healthy human subjects.en_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.rights.copyrightCopyright 2006 American Society for Microbiology. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal link for access to the definitive, published version.en_AU
gro.date.issued2006
gro.hasfulltextFull Text


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record